Humana Inc. (NYSE:HUM) Shares Sold by Barrow Hanley Mewhinney & Strauss LLC

Barrow Hanley Mewhinney & Strauss LLC cut its position in Humana Inc. (NYSE:HUM) by 88.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 71,336 shares of the insurance provider’s stock after selling 566,499 shares during the period. Barrow Hanley Mewhinney & Strauss LLC owned approximately 0.06% of Humana worth $18,099,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of HUM. FPC Investment Advisory Inc. purchased a new position in shares of Humana during the 4th quarter valued at about $27,000. Centricity Wealth Management LLC purchased a new position in Humana during the fourth quarter valued at approximately $30,000. LFA Lugano Financial Advisors SA lifted its holdings in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the period. OFI Invest Asset Management purchased a new stake in Humana in the 4th quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. grew its stake in shares of Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 60 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.37% of the stock is currently owned by insiders.

Humana Price Performance

HUM stock opened at $263.95 on Monday. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $31.86 billion, a PE ratio of 26.53, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The business has a 50 day simple moving average of $270.14 and a 200-day simple moving average of $273.49.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. The ex-dividend date is Friday, March 28th. Humana’s payout ratio is presently 35.58%.

Wall Street Analyst Weigh In

HUM has been the subject of several analyst reports. Truist Financial boosted their target price on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. StockNews.com lowered shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, March 18th. Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Finally, Piper Sandler boosted their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Eighteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Humana has a consensus rating of “Hold” and a consensus price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.